NCT06619587: A trial that was reported late by Genentech, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06619587 |
|---|---|
| Title | A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 14, 2024 |
| Completion date | Nov. 30, 2028 |
| Required reporting date | Nov. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 6, 2025 |
| Days late | None |